e-learning
resources
Paris 2018
Wednesday, 19.09.2018
Lung cancer: novel molecular markers and mechanisms
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
TRAP1 downregulation could overcome gefitinib resistance in NSCLC via EMT reversal
K. Hwang (Iksan, Republic of Korea), S. Oh (Iksan, Republic of Korea), E. Jeong (Iksan, Republic of Korea), H. Kim (Iksan, Republic of Korea)
Source:
International Congress 2018 – Lung cancer: novel molecular markers and mechanisms
Session:
Lung cancer: novel molecular markers and mechanisms
Session type:
Oral Presentation
Number:
5376
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Hwang (Iksan, Republic of Korea), S. Oh (Iksan, Republic of Korea), E. Jeong (Iksan, Republic of Korea), H. Kim (Iksan, Republic of Korea). TRAP1 downregulation could overcome gefitinib resistance in NSCLC via EMT reversal. 5376
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Prx1 modulates the chemosensitivity of lung cancer to docetaxel through suppression of FOXO1-induced apoptosis
Source: Annual Congress 2012 - New insights in the pathology of lung cancer
Year: 2012
The upregulation of Osteopontin mediates acquired resistance to EGFR-TKI in NSCLC through Integrin/FAK signaling
Source: Virtual Congress 2020 – Biological mechanisms of lung cancer
Year: 2020
Adenovirus-mediated E2F-1 gene transfer in nonsmall-cell lung cancer induces cell growth arrest and apoptosis
Source: Eur Respir J 2002; 20: 703-709
Year: 2002
Prx1 provides resistance to docetaxel-induced apoptosis in lung cancer cells
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Salinomycin suppresses TGF-ß1-induced EMT by down-regulating MMP-2,9 via AMPK-SIRT1 pathway in a non-small cell lung cancer
Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells
Year: 2017
Inhibition of hypoxia-induced phenotype alterations through epithelial-mesenchymal transition (EMT) in lung cancer by gene modulation of phosphorylation sites in tumor suppressor PTEN
Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics
Year: 2011
Adaptation to hypoxia leads to apoptosis resistance to cisplatin in non-small cell lung cancer (NSCLC) cell line
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
Potential therapeutic significance of CIK cells in gefitinib resistant NSCLC with EGFR mutations
Source: Annual Congress 2011 - Progress in pathology of lung cancer
Year: 2011
Blocking VEGF does not induce proapoptotic effects in the NSCLC cell line A549
Source: Annual Congress 2010 - New insights in the pathology of lung cancer
Year: 2010
Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC
Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers
Year: 2020
The selection of candidate microRNA biomarkers of acquired drug resistance in the lung adenocarcinoma cells treated with EGFR TKI
Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD
Year: 2019
Growth arrest and apoptosis induced by E2F-1 is associated with downregulation of p21 and uncoupling of S-phase and mitosis in NSCLC
Source: Eur Respir J 2001; 18: Suppl. 33, 475s
Year: 2001
Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker?
Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology
Year: 2007
Functional expressions of EGFP/LKB1 and its kinase domain induced apoptosis and enhanced chemosensitivity in lung cancer cell lines
Source: Eur Respir J 2004; 24: Suppl. 48, 5s
Year: 2004
Histone deacetylase inhibitor panobinostat reduces hypoxia-related cisplatin resistance in NSCLC cells by HDAC-mediated Hifalpha destabilization
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
The role of Pgp, MRP and LRP expression in chemotherapy response of small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 78s
Year: 2004
Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy
Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer
Year: 2019
p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance
Source: Eur Respir J 2001; 18: Suppl. 33, 230s
Year: 2001
Prognostic significance and correlation between Akt phosphorylation and loss of PTEN protein expression in non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 458s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept